没看懂？_老虎社区_美港股上老虎

鼠标汉
2020-06-10

没看懂？

中国生物制药(01177)拟按“2送1”基准发行红股

中国生物制药(01177)发布公告，董事会建议按持有每两股现有股份获发一股新股份的...

中国生物制药(01177)拟按“2送1”基准发行红股

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":956710366,"tweetId":"956710366","gmtCreate":1591791729155,"gmtModify":1704196929515,"author":{"id":3520725609449860,"idStr":"3520725609449860","authorId":3520725609449860,"authorIdStr":"3520725609449860","name":"鼠标汉","avatar":"https://static.tigerbbs.com/f50839e80af14727c32c18f0ddbf14b3","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":5,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>没看懂？</p></body></html>","htmlText":"<html><head></head><body><p>没看懂？</p></body></html>","text":"没看懂？","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/956710366","repostId":2042725007,"repostType":2,"repost":{"id":"2042725007","pubTimestamp":1591784503,"share":"https://www.laohu8.com/m/news/2042725007?lang=&edition=full","pubTime":"2020-06-10 18:21","market":"hk","language":"zh","title":"中国生物制药(01177)拟按“2送1”基准发行红股","url":"https://stock-news.laohu8.com/highlight/detail?id=2042725007","media":"智通财经网","summary":"中国生物制药(01177)发布公告，董事会建议按持有每两股现有股份获发一股新股份的...","content":"<html><body><article>\n<p>智通财经APP讯，<a href=\"https://laohu8.com/S/01177\">中国生物制药</a>(01177)发布公告，董事会建议按持有每两股现有股份获发一股新股份的基准，发行红利股份予于记录日期名列于公司股东名册的合资格股东。</p><p>假设于记录日期前并无进一步发行或回购股份，按本公告日期已发行125.82亿股现有股份的基准，预期根据发行红股将予配发及发行合共62.91亿股新股份，占公司于本公告日期的现有已发行股本50%，或经发行红股扩大后公司已发行股本33.33%。于发行红股完成后，将有合共188.73亿股股份。</p><p>于本公告日期，公司法定股本为5亿港元，分为200亿股股份。为使公司在日后的发展有更大灵活性，董事会建议透过增设100亿股额外新股份，增加公司法定股本至7.50亿港元，分为300亿股股份。有关新股份于发行后在各方面与现有股份享有同等权利。增加法定股本须待股东于股东特别大会上通过一项普通决议案批准。</p> </article></body></html>","source":"highlight_zhitongcaijin","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>中国生物制药(01177)拟按“2送1”基准发行红股</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n中国生物制药(01177)拟按“2送1”基准发行红股\n</h2>\n\n<h4 class=\"meta\">\n\n\n2020-06-10 18:21 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/308763.html><strong>智通财经网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，中国生物制药(01177)发布公告，董事会建议按持有每两股现有股份获发一股新股份的基准，发行红利股份予于记录日期名列于公司股东名册的合资格股东。假设于记录日期前并无进一步发行或回购股份，按本公告日期已发行125.82亿股现有股份的基准，预期根据发行红股将予配发及发行合共62.91亿股新股份，占公司于本公告日期的现有已发行股本50%，或经发行红股扩大后公司已发行股本33.33%。于...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/308763.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://img.zhitongcaijing.com/gonggao/ztcj_announce_13.jpeg?x-oss-process=image/format,jpg/quality,Q_100/resize,h_300","relate_stocks":{"01177":"中国生物制药"},"source_url":"http://www.zhitongcaijing.com/content/detail/308763.html","is_english":false,"share_image_url":"https://static.laohu8.com/6ca2dcdccfa2217fb20a0351f4efe814","article_id":"2042725007","content_text":"智通财经APP讯，中国生物制药(01177)发布公告，董事会建议按持有每两股现有股份获发一股新股份的基准，发行红利股份予于记录日期名列于公司股东名册的合资格股东。假设于记录日期前并无进一步发行或回购股份，按本公告日期已发行125.82亿股现有股份的基准，预期根据发行红股将予配发及发行合共62.91亿股新股份，占公司于本公告日期的现有已发行股本50%，或经发行红股扩大后公司已发行股本33.33%。于发行红股完成后，将有合共188.73亿股股份。于本公告日期，公司法定股本为5亿港元，分为200亿股股份。为使公司在日后的发展有更大灵活性，董事会建议透过增设100亿股额外新股份，增加公司法定股本至7.50亿港元，分为300亿股股份。有关新股份于发行后在各方面与现有股份享有同等权利。增加法定股本须待股东于股东特别大会上通过一项普通决议案批准。","news_type":1},"isVote":1,"tweetType":1,"viewCount":1447,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":7,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}